USPTO Examiner XIE XIAOZHEN - Art Unit 1674

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19058528COAGULATION MOLD, A KIT AND A METHOD FOR PREPARING A COAGULATED BLOOD MASSFebruary 2025April 2025Allow200YesNo
19037555MAMMALIAN CELL POPULATION AND MEDICAMENTS FOR CELL THERAPIES IN HUMANS AND IMPROVED CELL CULTIVATION METHODSJanuary 2025January 2026Allow1110YesNo
19032762COAGULATION MOLD, A KIT AND A METHOD FOR PREPARING A COAGULATED BLOOD MASSJanuary 2025January 2026Allow1221YesNo
18982853PHOSPHORYLATED ANTIGEN AND ANTIBODY AT SER23 SITE OF PGAM1 PROTEIN AS WELL AS PREPARATION METHODS AND APPLICATIONSDecember 2024August 2025Allow821YesNo
18861616COLLAGEN HYDROLYSATE COMPOSITION FOR REDUCING JOINT PAIN AFTER EXERCISEOctober 2024June 2025Allow700YesNo
18861520HYDROGEL COMPOSITION, METHOD FOR PRODUCING THE SAME, AND USE THEREOF FOR STEM CELL MIMETIC PEPTIDE SUPPLEMENTATIONOctober 2024January 2026Abandon3211NoNo
18783156COAGULATION MOLD, A KIT AND A METHOD FOR PREPARING A COAGULATED BLOOD MASSJuly 2024June 2025Allow1101YesNo
18750971PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCERJune 2024September 2024Allow301YesNo
18746802ImmunoconjugatesJune 2024October 2025Allow1601YesNo
18627131SCFV-FC DIMERS THAT BIND TRANSFORMING GROWTH FACTOR-BETA1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITYApril 2024July 2025Allow1510YesNo
18425954Use of C-Type Natriuretic Peptide Variants to Treat Skeletal DysplasiaJanuary 2024August 2025Allow1901YesNo
18407929ACTIVIN RECEPTOR TYPE IIB VARIANTS AND METHODS OF USE THEREOFJanuary 2024December 2024Allow1100YesNo
18406593TREATMENT FOR BONE DISEASESJanuary 2024March 2026Allow2611YesNo
18391146METHODS AND COMPOSITIONS FOR REGENERATING TISSUESDecember 2023December 2024Allow1200YesNo
18492150MODIFIED-IgG ANTIBODIES THAT BIND TRANSFORMING GROWTH FACTOR-BETA1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITYOctober 2023July 2024Allow900YesNo
18488796COMPOSITIONS AND METHODS OF USE OF INTERLEUKIN-10 IN COMBINATION WITH IMMUNE CHECK-POINT PATHWAY INHIBITORSOctober 2023December 2025Allow2521YesNo
18482891Compositions and Methods of Treatment for Various Conditions using High-Molecular Weight Hyaluronic AcidOctober 2023May 2025Allow2012YesNo
18279476LA PROTEIN AS A NOVEL REGULATOR OF OSTEOCLASTOGENESISAugust 2023November 2024Abandon1511NoNo
18457861ANTI-ROR2 ANTIBODIES, ANTIBODY FRAGMENTS, THEIR IMMUNOCONJUGATES AND USES THEREOFAugust 2023March 2025Allow1911YesNo
18352366TUNABLE SILK-BASED BIOMATERIALS WITH SACCHARIDE SUBSTITUTIONS, AND METHODS OF PRODUCING THE SAMEJuly 2023February 2025Allow1911YesNo
18317277COMPOSITIONS FOR TREATING AUTOIMMUNE ARTHRITISMay 2023August 2024Allow1511YesNo
18034867BCMA/TACI ANTIGEN-BINDING MOLECULESMay 2023February 2026Allow3300YesNo
18301839MAMMALIAN CELL POPULATION AND MEDICAMENTS FOR CELL THERAPIES IN HUMANS AND IMPROVED CELL CULTIVATION METHODSApril 2023October 2024Allow1831YesNo
18031536HEMATOPOIETIC STEM CELL ENGRAFTMENT WITH A COMBINATION OF AGENTSApril 2023December 2025Allow3300YesNo
18177642CARTILAGE-HOMING PEPTIDESMarch 2023December 2024Abandon2101NoNo
18175849Methods of Using IL-1beta CompoundsFebruary 2023February 2025Allow2410YesNo
18175163TWISTED GASTRULATION POLYPEPTIDES AND USES THEREOFFebruary 2023July 2024Allow1611YesNo
18114832IL-23R ANTAGONISTS TO REPROGRAM INTRATUMORAL T REGULATORY CELLS INTO EFFECTOR CELLSFebruary 2023September 2024Allow1801YesNo
18166211ANTI-SCLEROSTIN ANTIBODIES AND METHODS OF USEFebruary 2023September 2024Allow1901YesNo
18165203METHODS FOR TREATING SKIN INFECTION BY ADMINISTERING AN IL-4R ANTAGONISTFebruary 2023February 2026Abandon3631NoNo
18162769ANTI-CD154 ANTIBODY HAVING IMPROVED BINDING, FUNCTIONAL AND SAFETY CHARACTERISTICS AND USE IN HUMAN IMMUNOTHERAPYFebruary 2023February 2026Allow3601YesNo
18157689SAPOSIN C PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CANCERJanuary 2023September 2024Allow1921YesNo
18088272DOSAGE REGIMEN FOR PEGYLATED INTERFERONDecember 2022May 2025Allow2921YesNo
18062608GREMLIN-1 INHIBITOR FOR THE TREATMENT OF A BONE FRACTURE OR BONE DEFECTDecember 2022October 2024Allow2311YesNo
17996920MECHANICAL AND BIOCHEMICAL ACTIVATION AND CONTROL OF SKELETAL STEM CELLS FOR CARTILAGE REGENERATIONOctober 2022March 2026Allow4111YesNo
18046810COMPOSITIONS AND METHODS FOR TARGETED THERAPEUTIC DELIVERY TO BONEOctober 2022January 2025Allow2821YesNo
17903910COMPOSITIONS AND METHODS FOR DEGENERATIVE DISC REGENERATIONSeptember 2022March 2025Allow3021YesNo
17776835COMPOSITION FOR PREVENTING OR TREATING BONE DISEASES COMPRISING CCR2May 2022September 2025Allow4101YesNo
17663384INTERLEUKIN-2/INTERLEUKIN-2 RECEPTOR ALPHA FUSION PROTEINS AND METHODS OF USEMay 2022September 2024Allow2811YesNo
17727876POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFA AND IL-23April 2022September 2025Allow4110YesNo
17724632Targeting Synaptogyrin-3 in Tauopathy TreatmentApril 2022November 2025Abandon4301NoNo
17763902PHARMACEUTICAL COMPOSITION, COMPRISING RECOMBINANT STABILIZED GALECTIN 9 PROTEIN, FOR PREVENTION OR TREATMENT OF RHEUMATOID ARTHRITIS AND BONE DISEASEMarch 2022August 2025Allow4111YesNo
17701748METHODS AND COMPOSITIONS FOR TREATING SUBJECTS HAVING RHEUMATOID ARTHRITISMarch 2022January 2026Abandon4611NoNo
17698602BONE REPAIR PRODUCT AND METHODS OF USE THEREOFMarch 2022February 2025Allow3521YesNo
17761485METHODS OF TREATING AUTOIMMUNE DISEASES USING INTERLEUKIN-17 (IL-17) ANTAGONISTSMarch 2022August 2025Allow4101YesNo
17692818METHODS OF IMPROVING SPINAL FUSION WITH ABALOPARATIDEMarch 2022August 2025Allow4111YesNo
17633894HLA-DR/CII PEPTIDE COMPLEXES FOR TREATING ARTHRITISFebruary 2022February 2026Allow4811YesNo
17618808RECOMBINANT FACTOR VIII-FC FOR TREATING HEMOPHILIA AND LOW BONE MINERAL DENSITYDecember 2021October 2025Abandon4701NoNo
17616391ANTIBODY TARGETING THE VP-1 PROTEIN, FRAGMENTS THEREOF, AND USES OF SAME FOR DETECTING INFECTION WITH THE BK POLYOMAVIRUSDecember 2021April 2025Allow4000YesNo
17541992USE OF C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT OSTEOARTHRITISDecember 2021September 2024Allow3421YesNo
17616126USES OF SYNTHETIC LETHAL PARTNERS FOR TREATMENT OF CANCERDecember 2021October 2025Allow4611YesNo
17532584METHODS OF TREATING LIVER DISEASENovember 2021February 2026Allow5111YesNo
17610319PEPTIDES AND CONJUGATES FOR TREATMENT OF ARTHRITISNovember 2021September 2025Abandon4710NoNo
17608351A STABLE LYOPHILIZED FORMULATION FOR HYBRID FC FUSED G-CSFNovember 2021August 2025Allow4510YesNo
17517533Method of Treating OsteoarthritisNovember 2021December 2024Allow3731YesNo
17598049COMPOSITION FOR PROMOTING CARTILAGE TISSUE REGENERATIONSeptember 2021February 2025Abandon4101NoNo
17438634A METHOD FOR IMMUNOSUPPRESSIONSeptember 2021April 2025Abandon4301NoNo
17470455BIOMARKERS AND METHODS FOR ASSESSING PSORIATIC ARTHRITIS DISEASE ACTIVITYSeptember 2021January 2024Abandon2941NoNo
17465092METHOD FOR PURIFYING ACTIVE POLYPEPTIDES OR IMMUNOCONJUGATESSeptember 2021February 2025Abandon4110NoNo
17276916Human Monoclonal Antibody Binding Specifically to Human Hmgb1, and Pharmaceutical Composition for Treating or Preventing Alzheimer's Disease Containing Said Human Monoclonal AntibodyAugust 2021February 2025Allow4701YesNo
17433295COMBINED THERAPIES OF ACTIVATABLE IMMUNE CHECKPOINT INHIBITORS AND CONJUGATED ACTIVATABLE ANTIBODIESAugust 2021February 2025Abandon4201NoNo
17432185ANTI-CSP ANTIBODY VARIANTSAugust 2021June 2025Abandon4601NoNo
17402325MULTIFUNCTIONAL MOLECULES THAT BIND TO T CELL RELATED CANCER CELLS AND USES THEREOFAugust 2021April 2025Allow4411YesNo
17430319HIGH AFFINITY ENGINEERED T-CELL RECEPTORS TARGETING CMV INFECTED CELLSAugust 2021February 2026Allow5421YesNo
17286355MARKER FOR DETERMING CRITICAL STAGE KIDNEY DISEASEAugust 2021February 2025Abandon4601NoNo
17427559IMMUNOASSAY METHOD FOR FREE AIM IN BIOLOGICAL SAMPLE, AND ASSAY KITJuly 2021December 2024Allow4010YesNo
17425599Composition for predicting clinical stage of Alzheimer's disease and kit using the sameJuly 2021December 2025Allow5321YesNo
17443012COMPOSITION AND METHOD FOR DELIVERY OF BMP-2 AMPLIFIER/CO-ACTIVATOR FOR ENHANCEMENT OF OSTEOGENESISJuly 2021August 2024Allow3721YesNo
17422556MUTATED INTERLEUKIN-34 (IL-34) POLYPEPTIDES AND USES THEREOF IN THERAPYJuly 2021July 2025Allow4811YesNo
17422075ANTI-CD40 ANTIBODIES FOR USE IN TREATMENT OF HIDRADENITIS SUPPURATIVAJuly 2021May 2025Allow4611YesNo
17422033COMPOSITIONS AND METHODS FOR PREDICTING LUNG FUNCTION DECLINE IN IDIOPATHIC PULMONARY FIBROSISJuly 2021August 2025Allow4911YesNo
17419932TEST METHOD FOR ULCERATIVE COLITIS AND PRIMARY SCLEROSING CHOLANGITISJune 2021November 2025Allow5221YesNo
17298865PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOFJune 2021November 2024Allow4201YesNo
17290016BIOMARKER PROTEINS FOR DIAGNOSING ALZHEIMER'S DEMENTIA AND USE THEREOFApril 2021November 2024Abandon4301NoNo
17288234MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO CD20April 2021August 2024Allow4001YesNo
17287367ANTI-IL-25 ANTIBODIES AND USE THEREOFApril 2021December 2024Allow4411YesNo
17232145CYCLIC PEPTIDE FROM NOVEL BONE MORPHOGENETIC PROTEIN 2, PREPARATION METHOD THEREFOR AND APPLICATION THEREOFApril 2021August 2024Allow4011YesNo
17282577MENISCUS REGENERATION MATERIALApril 2021June 2025Allow5021YesNo
17211261SYSTEMS, COMPOSITIONS, AND METHODS FOR TRANSPLANTATIONMarch 2021November 2024Abandon4431YesNo
17279359AXL-SPECIFIC ANTIBODIES FOR TREATMENT OF NON-SMALL CELL LUNG CANCERMarch 2021December 2024Abandon4501NoNo
17256509ANABOLIC TARGETING STEM CELL GENE THERAPY FOR OSTEOPOROSISDecember 2020November 2024Abandon4711NoNo
17053602USE OF CANAKINUMABNovember 2020February 2026Abandon6031NoNo
17030416Personalized Immunotherapies for Reduction of Brain Inflammation and Suicide PreventionSeptember 2020November 2024Abandon5021YesNo
16967922METHODS FOR TREATING HETEROTOPIC OSSIFICATIONAugust 2020March 2025Allow5621YesNo
16945494METHODS OF REDUCING AGGREGATION OF IL-1RAJuly 2020June 2025Abandon5951YesNo
16960704CALRETICULIN BINDING CONSTRUCTS AND ENGINEERED T CELLS FOR THE TREATMENT OF DISEASESJuly 2020December 2024Allow5321YesNo
16863630INJECTABLE BONE MORPHOGENETIC PROTEINApril 2020August 2024Allow5241YesNo
16760731HETEROTOPIC OSSIFICATION AND METHOD OF TREATMENTApril 2020October 2024Allow5441YesNo
16858301METHOD OF DIAGNOSIS AND TREATMENT OF RHEUMATOID ARTHRITISApril 2020June 2025Allow6061YesYes
16805481IL-4/IL-13 PATHWAY INHIBITORS FOR ENHANCED EFFICACY IN TREATING CANCERFebruary 2020August 2024Allow5431YesNo
16670395ANTI-TNF-ALPHA POLYPEPTIDE COMPOSITION AND USE THEREOFOctober 2019October 2025Abandon6031NoYes
16659604NON-RESORBABLE BONE ALLOGRAFTS AND METHOD FOR MAKING SAMEOctober 2019October 2023Abandon4820YesNo
16485574MYOMERGER POLYPEPTIDES, NUCLEIC ACID MOLECULES, CELLS, AND RELATED METHODSAugust 2019August 2025Abandon6041YesNo
15855398COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING DISEASES, CONDITIONS OR PROCESSES CHARACTERIZED BY ABERRANT FIBROBLAST PROLIFERATION AND EXTRACELLULAR MATRIX DEPOSITIONDecember 2017September 2019Allow2101YesNo
15553930ANTI-TGF-BETA ANTIBODY FOR THE TREATMENT OF FANCONI ANEMIAAugust 2017August 2019Allow2411YesNo
15165150ANTIBODIES TARGETING BONE MORPHOGENETIC PROTEIN 9 (BMP9) AND METHODS THEREFORMay 2016April 2018Allow2201YesNo
14757770Method of treating skeletal dysplasias using vessel dilatorDecember 2015February 2018Allow2621YesNo
14875812BINDING PROTEINS SPECIFIC FOR INSULIN-LIKE GROWTH FACTORS AND USES THEREOFOctober 2015June 2017Allow2101YesNo
14767117HIGHLY GALACTOSYLATED ANTI-TNF-ALPHA ANTIBODIES AND USES THEREOFAugust 2015October 2018Allow3811YesNo
14812908Immunoconjugates for the Treatment of TumoursJuly 2015June 2017Allow2211YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner XIE, XIAOZHEN.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
4
Examiner Affirmed
3
(75.0%)
Examiner Reversed
1
(25.0%)
Reversal Percentile
37.9%
Lower than average

What This Means

With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
27
Allowed After Appeal Filing
6
(22.2%)
Not Allowed After Appeal Filing
21
(77.8%)
Filing Benefit Percentile
29.2%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 22.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner XIE, XIAOZHEN - Prosecution Strategy Guide

Executive Summary

Examiner XIE, XIAOZHEN works in Art Unit 1674 and has examined 174 patent applications in our dataset. With an allowance rate of 86.8%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 45 months.

Allowance Patterns

Examiner XIE, XIAOZHEN's allowance rate of 86.8% places them in the 65% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.

Office Action Patterns

On average, applications examined by XIE, XIAOZHEN receive 2.40 office actions before reaching final disposition. This places the examiner in the 69% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by XIE, XIAOZHEN is 45 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +25.9% benefit to allowance rate for applications examined by XIE, XIAOZHEN. This interview benefit is in the 73% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 28.0% of applications are subsequently allowed. This success rate is in the 50% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 40.4% of cases where such amendments are filed. This entry rate is in the 62% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 133.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 85% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 85.7% of appeals filed. This is in the 79% percentile among all examiners. Of these withdrawals, 87.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 43.4% are granted (fully or in part). This grant rate is in the 36% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 20.7% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.0% of allowed cases (in the 77% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.